Investor Overview

Living Systems Intelligence | CytosAI is dedicated to transparency, long-term value creation, and the ethical advancement of biotechnological solutions.

Stock Performance (NYSE: LCYT)

$142.851.24 (0.87%)

Open: 141.50High: 143.20Low: 141.10Vol: 1.2M

Market Cap

$42.8B

Enterprise Value: $40.1B

Next Earnings

Oct 24

Q3 2025 Results & Webcast

Material Updates

View Archive →

2026-01-15

LSI Completes Phase III Trial for Cytos-V

Clinical endpoints met with statistical significance. FDA filing submission scheduled for Q2.

2026-01-04

Annual Shareholder Letter Published

Reviewing 2025 performance and 2026 strategic outlook.

2025-12-20

CytosAI Announces Strategic Partnership

New collaboration with Major Pharma Inc. to accelerate drug discovery.

Investor Presentation

Download the latest overview of our strategic roadmap and financial targets.

Email Alerts

Receive SEC filings and press releases directly.